“Whoa! It’s like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Is interleukin-1 beta a triggering factor for restenosis?

Is interleukin-1 beta a triggering factor for restenosis? See article by Chamberlain et al. 9 (pages 156–165) in this issue. Today, more than 20 years after percutaneous transluminal coronary angioplasty (PTCA) was introduced into the clinic by Andreas Grüntzig 1 , PTCA has become a well-established and routine procedure for myocardial revascularization of patients with coronary heart disease (CHD). However, restenosis occurs in these patients at a rate between 30 and 50%, despite a successful initial procedure (for an extensive reviews see Refs. 2–5 ). More than 60 large-scale clinical trials later, we are still struggling to understand why restenosis occurs in some but not in others, and why after 20 years the rate of restenosis is virtually unchanged, despite the availability of modern therapeutics and extensive knowledge in vascular biology 6–8 . The paper presented in this issue 9 intriguingly puts interleukin-1β (IL-1β) onto center stage as a possible triggering factor in the initiation process of restenosis, and may provide us with a handle for successful therapeutic intervention. According to current concepts, three processes (phases) have been postulated to lead to post PTCA restenosis in patients 10 . Phase I is the acute lumen loss which occurs in some patients, and is termed elastic ‘recoil’. Recoil develops within hours of the intervention and appears to be the consequence of overstretching. Phase II is the mural thrombus formation which results from endothelium removal, and the exposure of deep vascular structures and induction of procoagulant factors. These thrombi are rich in cytokines and growth factors, including interleukin-1β, platelet-derived growth factor (PDGF), and transforming growth factor-β (TGF-β) 11 . Finally, … Full Text of this Article * Tel.: +1-203-401-3330, ext. 325; fax: +1-203-401-3337 boemar@curagen.com http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Research Oxford University Press

Is interleukin-1 beta a triggering factor for restenosis?

Abstract

Is interleukin-1 beta a triggering factor for restenosis? See article by Chamberlain et al. 9 (pages 156–165) in this issue. Today, more than 20 years after percutaneous transluminal coronary angioplasty (PTCA) was introduced into the clinic by Andreas Grüntzig 1 , PTCA has become a well-established and routine procedure for myocardial revascularization of patients with coronary heart disease (CHD). However, restenosis occurs in these patients at a rate between 30 and 50%, despite a successful initial procedure (for an extensive reviews see Refs. 2–5 ). More than 60 large-scale clinical trials later, we are still struggling to understand why restenosis occurs in some but not in others, and why after 20 years the rate of restenosis is virtually unchanged, despite the availability of modern therapeutics and extensive knowledge in vascular biology 6–8 . The paper presented in this issue 9 intriguingly puts interleukin-1β (IL-1β) onto center stage as a possible triggering factor in the initiation process of restenosis, and may provide us with a handle for successful therapeutic intervention. According to current concepts, three processes (phases) have been postulated to lead to post PTCA restenosis in patients 10 . Phase I is the acute lumen loss which occurs in some patients, and is termed elastic ‘recoil’. Recoil develops within hours of the intervention and appears to be the consequence of overstretching. Phase II is the mural thrombus formation which results from endothelium removal, and the exposure of deep vascular structures and induction of procoagulant factors. These thrombi are rich in cytokines and growth factors, including interleukin-1β, platelet-derived growth factor (PDGF), and transforming growth factor-β (TGF-β) 11 . Finally, … Full Text of this Article * Tel.: +1-203-401-3330, ext. 325; fax: +1-203-401-3337 boemar@curagen.com
Loading next page...
 
/lp/oxford-university-press/is-interleukin-1-beta-a-triggering-factor-for-restenosis-5tVw5ejKbV

Sorry, we don’t have permission to share this article on DeepDyve,
but here are related articles that you can start reading right now:

Explore the DeepDyve Library

How DeepDyve Works

Spend time researching, not time worrying you’re buying articles that might not be useful.

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.

All the latest content is available, no embargo periods.

See the journals in your area

Simple and Affordable Pricing

14-day free trial. Cancel anytime, with a 30-day money-back guarantee.

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$40/month

Best Deal — 25% off

Annual Plan

  • All the features of the Professional Plan, but for 25% off!
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$30/month
billed annually